Back to Search
Start Over
Update of EULAR recommendations for the treatment of systemic sclerosis
- Source :
- Kowal-Bielecka, O, Fransen, J, Avouac, J, Becker, M, Kulak, A, Allanore, Y, Distler, O, Clements, P J, Cutolo, M, László, C, Damjanov, N, Del Galdo, F, Denton, C P, Distler, J H W, Foeldvari, I, Kim, F, Frerix, M, Furst, D E, Guiducci, S, Hunzelmann, N, Khanna, D, Matucci-Cerinic, M, Herrick, A, Van Den Hoogen, F, van Laar, J M, Riemekasten, G, Silver, R, Smith, V, Sulli, A, Tarner, I, Tyndall, A, Welling, J, Wigley, F M, Valentini, G, Walker, U A, Zulian, F & Müller-Ladner, U 2017, ' Update of EULAR recommendations for the treatment of systemic sclerosis ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2016-209909, Annals of the Rheumatic Diseases, Vol. 76, no. 8, p. 1327-1339 (2016), Annals of the Rheumatic Diseases, Volume 76, Issue 8
- Publication Year :
- 2017
-
Abstract
- The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
- Subjects :
- Endothelin Receptor Antagonists
Lung Diseases
Kidney Disease
Delphi Technique
Gastrointestinal Diseases
systemic sclerosis
Scleroderma Renal Crisis
Placebo-controlled study
Angiotensin-Converting Enzyme Inhibitors
Lung Disease
Scleroderma
0302 clinical medicine
Glucocorticoid
Phosphodiesterase 5 Inhibitor
Immunology and Allergy
skin and connective tissue diseases
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina
integumentary system
treatment
genetics and molecular biology (all)
Hematopoietic Stem Cell Transplantation
cyclophosphamide
methotrexate
Pulmonary
Orvostudományok
Serotonin Uptake Inhibitor
3. Good health
Europe
Systematic review
Hypertension
Serotonin Uptake Inhibitors
Cyclophosphamide
Methotrexate
Systemic Sclerosis
Treatment
Fingers
Fluoxetine
Glucocorticoids
Humans
Hypertension, Pulmonary
Kidney Diseases
Phosphodiesterase 5 Inhibitors
Prostaglandins I
Pyrazoles
Pyrimidines
Raynaud Disease
Rheumatology
Scleroderma, Systemic
Ulcer
Immunology
Biochemistry, Genetics and Molecular Biology (all)
030211 gastroenterology & hepatology
Endothelin Receptor Antagonist
Selective Serotonin Reuptake Inhibitors
medicine.drug
Human
medicine.medical_specialty
Gastrointestinal Disease
Klinikai orvostudományok
Riociguat
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
medicine
Finger
biochemistry
Intensive care medicine
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine
Systemic Sclerosi
030203 arthritis & rheumatology
business.industry
Systemic
Angiotensin-Converting Enzyme Inhibitor
medicine.disease
Transplantation
Clinical research
Pyrimidine
immunology and allergy
rheumatology
immunology
Pyrazole
Physical therapy
business
Rheumatism
Subjects
Details
- Language :
- English
- ISSN :
- 00034967 and 14682060
- Database :
- OpenAIRE
- Journal :
- Kowal-Bielecka, O, Fransen, J, Avouac, J, Becker, M, Kulak, A, Allanore, Y, Distler, O, Clements, P J, Cutolo, M, László, C, Damjanov, N, Del Galdo, F, Denton, C P, Distler, J H W, Foeldvari, I, Kim, F, Frerix, M, Furst, D E, Guiducci, S, Hunzelmann, N, Khanna, D, Matucci-Cerinic, M, Herrick, A, Van Den Hoogen, F, van Laar, J M, Riemekasten, G, Silver, R, Smith, V, Sulli, A, Tarner, I, Tyndall, A, Welling, J, Wigley, F M, Valentini, G, Walker, U A, Zulian, F & Müller-Ladner, U 2017, ' Update of EULAR recommendations for the treatment of systemic sclerosis ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2016-209909, Annals of the Rheumatic Diseases, Vol. 76, no. 8, p. 1327-1339 (2016), Annals of the Rheumatic Diseases, Volume 76, Issue 8
- Accession number :
- edsair.doi.dedup.....a904be7311b89a59835d8150ce5b9c69